OR Royalties Q3 2025 Earnings Report

OR Royalties EPS Results

• Actual EPS: N/A
• Consensus EPS: $0.21
• Beat/Miss: N/A
• One Year Ago EPS: N/A

OR Royalties Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $53.85 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

OR Royalties Announcement Details

• Quarter: Q3 2025
• Date: 11/5/2025
• Time: After Market Closes
• Conference Call Date: Thursday, November 6, 2025
• Conference Call Time: 10:00AM ET

OR Royalties (NYSE:OR) PLC (NYSE: OR) is a closed-ended investment company that specializes in acquiring and managing royalty interests in life science and pharmaceutical products. The company provides capital to biotechnology, specialty pharmaceutical and medical device companies in exchange for a share of future sales revenues. By focusing on royalties secured against marketed products, OR Royalties aims to deliver income and growth potential while minimizing the development and commercialization risks typically associated with direct equity stakes.

The company’s core activities include sourcing royalty transactions, structuring bespoke financing solutions and actively monitoring a diversified portfolio of assets. OR Royalties seeks opportunities across a wide range of therapeutic areas—including oncology, rare diseases and specialty care—and partners with established and emerging developers. Its investment mandate covers products already on the market as well as late-stage assets nearing regulatory approval.

Founded in 2021 and headquartered in London, OR Royalties has assembled a team of specialists with experience in pharmaceutical licensing, intellectual property valuation and clinical development. The portfolio spans multiple geographies, with royalties derived from sales in the United States, Europe and select international markets. This geographic diversification, coupled with exposure to different product life cycles, underpins the company’s strategy to generate steady, long-term cash flows for shareholders.

Governed by an independent board and led by a management team with deep transaction and clinical expertise, OR Royalties continues to expand its holdings through disciplined deal sourcing and rigorous due diligence. The firm’s transparent royalty model and focus on revenue-generating assets position it as a dedicated vehicle for investors seeking targeted exposure to healthcare innovations without direct operational involvement in drug development.